| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5753646 | SUMITOMO PHARMA AM | Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them |
Jun, 2021
(2 years ago) | |
| US9206135 | SUMITOMO PHARMA AM | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11364247 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 17 days from now) | |
| US10675287 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 17 days from now) | |
| US10695354 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 17 days from now) | |
| US10702536 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(1 year, 17 days from now) | |
| US9643929 | SUMITOMO PHARMA AM | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(2 years from now) | |
| US9763954 | SUMITOMO PHARMA AM | Therapeutical uses of eslicarbazepine |
Sep, 2028
(4 years from now) | |
| US9566244 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(4 years from now) | |
| US10912781 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(4 years from now) | |
| US8372431 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Apr, 2030
(5 years from now) | |
| US9750747 | SUMITOMO PHARMA AM | Treatments involving eslicarbazepine acetate or eslicarbazepine |
Aug, 2032
(8 years from now) | |
Aptiom is owned by Sumitomo Pharma Am.
Aptiom contains Eslicarbazepine Acetate.
Aptiom has a total of 12 drug patents out of which 1 drug patent has expired.
Expired drug patents of Aptiom are:
- US5753646
Aptiom was authorised for market use on 08 November, 2013.
Aptiom is available in tablet;oral dosage forms.
Aptiom can be used as treatment of partial-onset seizures in patients with epilepsy who have been previously treated with oxcarbazepine, treatment of partial-onset seizures in a patient with refractory partial-onset seizures, treatment of partial-onset seizures.
Drug patent challenges can be filed against Aptiom from 08 November, 2017.
The generics of Aptiom are possible to be released after 24 August, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-150) | Aug 27, 2018 |
| New Indication(I-715) | Aug 27, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2018 |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
NCE-1 date: 08 November, 2017
Market Authorisation Date: 08 November, 2013
Treatment: Treatment of partial-onset seizures in a patient with refractory partial-onset seizures; Treatment of partial-onset seizures; Treatment of partial-onset seizures in patients with epilepsy who have bee...
Dosage: TABLET;ORAL
APTIOM family patents
